Drug Profile


Alternative Names: AZD-0914; ETX-0914

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; National Institute of Allergy and Infectious Diseases
  • Class Antibacterials; Ketones; Oxazines; Oxazolidinones; Pyrimidines; Quinolines; Spiro compounds
  • Mechanism of Action DNA gyrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gonorrhoea

Most Recent Events

  • 19 Jan 2018 National Institute of Allergy and Infectious Diseases plans a phase I trial for Gonorrhoea in the US , (NCT03404167)
  • 06 Sep 2017 Zoliflodacin is still in phase II development for Gonorrhoea in USA (Entasis Therapeutics pipeline, September 2017)
  • 06 Jul 2017 Entasis Therapeutics and Global Antibiotic Research and Development Partnership agree to co-develop and co-promote Zoliflodacin in South Africa, USA, Thailand and World for Gonorrhoea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top